Prediction of massive bleeding in pancreatic surgery based on preoperative patient characteristics using a decision tree

Taiichi Wakiya1*, Keinosuke Ishido1, Norihisa Kimura1, Hayato Nagase1, Shunsuke Kubota1, Hiroaki Fujita1, Yusuke Hagiwara1, Taishu Kanda1, Masashi Matsuzaka2, Yoshihiro Sasaki2, Kenichi Hakamada1

1 Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan, 2 Department of Medical Informatics, Hirosaki University Hospital, Hirosaki, Aomori, Japan

* wakiya1979@hirosaki-u.ac.jp

Abstract

Massive intraoperative blood loss (IBL) negatively influence outcomes after surgery for pancreatic ductal adenocarcinoma (PDAC). However, few data or predictive models are available for the identification of patients with a high risk for massive IBL. This study aimed to build a model for massive IBL prediction using a decision tree algorithm, which is one machine learning method. One hundred and seventy-five patients undergoing curative surgery for resectable PDAC at our facility between January 2007 and October 2020 were allocated to training (n = 128) and testing (n = 47) sets. Using the preoperatively available data of the patients (34 variables), we built a decision tree classification algorithm. Of the 175 patients, massive IBL occurred in 88 patients (50.3%). Binary logistic regression analysis indicated that alanine aminotransferase and distal pancreatectomy were significant predictors of massive IBL occurrence with an overall correct prediction rate of 70.3%. Decision tree analysis automatically selected 14 predictive variables. The best predictor was the surgical procedure. Though massive IBL was not common, the outcome of patients with distal pancreatectomy was secondarily split by glutamyl transpeptidase. Among patients who underwent PD (n = 83), diabetes mellitus (DM) was selected as the variable in the second split. Of the 21 patients with DM, massive IBL occurred in 85.7%. Decision tree sensitivity was 98.5% in the training data set and 100% in the testing data set. Our findings suggested that a decision tree can provide a new potential approach to predict massive IBL in surgery for resectable PDAC.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) has the poorest prognosis of any cancer, worldwide [1]. In tackling this lethal disease, surgery has been one of the most fundamental treatment options [2–4]. Today, pancreatic cancer surgery outcomes have improved thanks to increasing experience and refinement in surgical technique, as well as centralization of patient
care to high-volume centers [5–10]. However, due to the technical complexity of the procedure, pancreatic cancer surgery with lymph node dissection sometimes causes massive intraoperative blood loss (IBL), even when performed by experienced surgeons in high-volume centers [11]. As a result, allogeneic blood transfusion (ABT) has become commonplace for patients undergoing surgery for PDAC [11–13].

Although ABT can be a lifesaving treatment during pancreatic cancer surgery, it can cause an immunomodulatory effect called transfusion related immunomodulation [14–16]. In 1973, Opelz et al. provided initial evidence for ABT-related immunomodulation [14, 15]. Since then, though there are various potentially confounding factors to consider [17–19], many studies have reported the harmful effects of ABT on the prognosis after cancer surgery [13, 16, 20, 21]. Likewise, past reports have shown the negative effects of ABT on the long-term postoperative outcomes of PDAC patients [13, 20–24]. We also previously revealed that intraoperative ABT was strongly associated with poor prognosis in patients who underwent resection with curative intent for resectable PDAC [25]. Thus, we need to establish alternate strategies to ABT to improve the prognosis of PDAC patients further.

If we can predict massive IBL before surgery, it is possible to avoid ABT using various creative alternatives such as preoperative autologous blood storage and intraoperative acute normovolemic hemodilution. However, to date, it has not been possible to predict the occurrence of massive IBL beforehand. An accurate and robust prediction model would ultimately contribute to a better prognosis in PDAC patients. Therefore, in this study, we designed a prediction model for massive IBL in pancreatic cancer surgery. Here, we have successfully developed a user-friendly decision tree that predicts massive IBL in surgery for patients with resectable PDAC.

**Materials and methods**

**Patients and study design**

This single-center, retrospective, observational study was approved by the institutional ethics committee (reference no. 2020–202). This study was registered at the Japan Registry of Clinical Trials (https://jRCT.niph.go.jp/, jRCT1020210001). Informed consent was obtained in the form of opt-out on our website (https://www.med.hirosaki-u.ac.jp/hospital/outline/research/research.html). This study was designed and carried out in accordance with the Declaration of Helsinki. Data has been reported in line with STROCSS 2019 criteria [26].

A total of 175 consecutive patients undergoing pancreatic surgery, with curative intent, for resectable PDAC at our facility between January 2007 and October 2020 were screened for study inclusion. Resectability status was made based on National Comprehensive Cancer Network guidelines. All patients had a confirmed pathologic diagnosis. In this study, we excluded the following cases: patients who had received neoadjuvant chemotherapy, anyone with remnant pancreatic cancer, or those with other synchronous malignancies.

**Perioperative variable selection**

Patient data were extracted from the medical records at our facilities. A total of 34 perioperative variables were selected from patient records, categorized into five groups: 1) patient demographics (n = 4), 2) comorbidities (n = 8), 3) laboratory values (n = 14), 4) tumor factors (n = 5), and 5) operative factors (n = 2).

**Surgical procedures and operative management**

We selected the type of pancreatic resection based on tumor location. Open pancreatoduodenectomy (PD) with lymph node dissections was usually performed on cases of pancreatic head
cancer. In cases of pancreatic body and tail cancer, open or minimally invasive distal pancreatico-
tectomy (DP) was performed with lymph node dissections. If we detected a swelling paraaortic lymph node, we generally performed paraaortic lymph node sampling during PD; whereas sampling was not routinely performed during DP. We performed a fresh frozen section analy-
sis to confirm if the pancreatic cut-end margin was clear of residual cancer. If residual cancer was present at the pancreatic cut end margin, we cut the pancreas further to reach negative margin status. If necessary, to achieve curative resection, we performed a total pancreatectomy (TP) with lymph node dissections.

Definition of massive IBL

In this study, we defined massive IBL as more than 20% of the estimated circulating blood vol-
volume (CBV), based on the model of Lundsgaard-Hansen [27]. We estimated the CBV using the follow-
ing formula; CBV (mL) = 70 x body weight (kg). The IBL was calculated based on the in/out balance of the operative field. At our institution, any fluid loss from the abdominal cavity including ascites, bile, and lymphatics is considered to be intraoperative bleeding.

Statistical analyses

Continuous variables were expressed as medians (ranges) and analyzed using nonparametric methods for non-normally distributed data (Mann–Whitney U-test). Categorical variables were reported as numbers (percentages) and analyzed using the chi-squared test or Fisher’s exact test, as appropriate. Variables with a significant relationship to massive IBL in univariate analysis were used in a binary logistic regression model. Before inputting variables, we per-
formed the Spearman correlation analysis and confirmed that there was no strong correlation (r >0.80) between the independent variables. Recurrence free survival (RFS) and Disease spe-
cific survival (DSS) were calculated using the Kaplan–Meier method, and differences in the survival rates between the massive IBL and non-massive IBL groups were compared using the log-rank test. RFS was defined as the time from the operation to the date of disease recurrence. DSS was defined as the time from the operation to the time of death due to PDAC, or the last follow-up time. This study was planned with a maximum follow-up period of five years. A differ-
ence was considered to be significant for values of P < 0.05. The statistical analyses were performed using IBM SPSS Statistics for Windows, Version 26.0 (IBM Corp, Armonk, NY, USA).

Decision tree analysis

We built a tree to predict occurrence of massive IBL using classification and regression trees (CART) analysis. Enrolled patients were divided into training and testing data sets, with a ratio of about 3:1. The training data included the patients who underwent pancreatic surgery between January 2007 and June 2018. The testing data included patients who had surgery between July 2018 and October 2020. The training set was used for generating the model. Each parameter was determined by performing a grid search for those with maximum accuracy. The development environment used for decision tree analysis was Python 3.6, implemented with scikit–learn 0.20 [28]. The developed software searched the training database for the factor that most effectively predicted massive IBL occurrence and its cut-off value. In brief, the decision tree was built using the following process: 1) identification of the single variable that, when used to split the dataset into two groups ("left and right children nodes"), best-mi-
imized impurity of massive IBL occurrence in each node, according to the Gini impurity index; 2) repetition of the splitting process within each child node leading to leaf nodes where no additional splitting achieved further reductions in node impurity. In addition, a restriction
was imposed on the tree construction such that nodes resulting from any given split needed to have at least five patients. We set a maximum tree depth of six to avoid overfitting. Nodes in binary recursive partitioning trees predict massive IBL occurrence categorically but, by evaluating node impurity, also offer associated probabilities. Finally, a massive IBL risk prediction model was created based on this analysis. Furthermore, the suitability and reproducibility of the model were validated using the testing data sets.

Results

Patient characteristics from the training and testing data sets

The clinical characteristics of the 175 enrolled patients are shown in Table 1. Of the 175 patients, 128 were used for the training data, and data sets from 47 patients (26.9%) were used as the testing data. Information on IBL is presented in Table 2. Of the 175 patients, 88 patients (50.3%) were included in the massive IBL group.

Comparison of the perioperative characteristics of the massive IBL and non-massive IBL groups

The massive IBL group demonstrated higher levels on liver function tests such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), glutamyl transpeptidase (GTP), and serum total bilirubin (Table 3). This is assumed to have been caused by obstructive jaundice. There were no significant differences in the comorbidities between the groups. Although the tumor related factors were almost similar among groups, the massive IBL group had higher incidences of lymphatic metastasis (P = 0.046). Massive IBL was significantly associated with PD (78.4 vs. 42.5%, P < 0.001) and portal vein resection (25.0 vs. 6.9%, P = 0.001).

Comparison of the postoperative outcomes of the massive IBL and non-massive IBL groups

Of the 88 patients with massive IBL, 33 (37.5%) received ABT (Table 4). The massive IBL group was associated with a higher frequency of postoperative complications (Clavien-Dindo grade ≥ 3, P = 0.001), especially in terms of the rate of pancreatic fistulas (with an International Study Group for Pancreatic Surgery (ISGPF) grade ≥ B) (20.5% vs. 6.9%, P = 0.009). Moreover, the IBL groups exhibited longer periods with regard to postoperative hospital stays (P < 0.001).

The RFS time was significantly shorter in the massive IBL group than in the non-massive IBL group (median survival time (MST), 12.4 vs. 14.5 months, P = 0.013). Likewise, the DSS was shorter in the massive IBL group (MST, 28.6 vs. 40.0 months, P = 0.1124) (Fig 1).

Binary logistic regression analysis

To predict the occurrence of massive IBL, we performed a binary logistic regression analysis. We set the occurrence of massive IBL as the dependent variable. Significant predictor variables linked with massive IBL, which were found through a univariate analysis (P<0.05), as listed in Table 3, were entered into a binary logistic regression analysis. Before inputting predictor variables, we performed the Spearman correlation analysis and confirmed that there was no strong correlation (r >0.80) between the independent variables. As a result, we found a strong correlation between AST and ALT (r >0.90, p <0.001). Thus, we selected ALT based on the p value in a univariate analysis. There were no outliers whose predicted values exceeded ± 2SD in the measured values.
### Table 1. Patient characteristics in data sets.

|                     | All cases (n = 175) | Training data (n = 128) | Testing data (n = 47) |
|---------------------|---------------------|------------------------|----------------------|
| Gender, male, n     | 91 (52.0)           | 65 (50.8)              | 26 (55.3)            |
| Age, year           | 70 (43–87)          | 70 (50–85)             | 72 (43–87)           |
| Body weight, kg     | 55.9 (34.0–85.0)    | 56.0 (34.0–85.0)       | 55.8 (37.0–77.4)     |
| Body mass index, kg/m² | 22.0 (14.1–36.3) | 22,3 (14.1–36.3)       | 21.8 (17.4–32.3)     |
| **Comorbidities**   |                     |                        |                      |
| Diabetes mellitus, n| 68 (38.9)           | 43 (33.6)              | 25 (53.2)            |
| Cancer history, n   | 35 (20.0)           | 21 (16.4)              | 14 (29.8)            |
| Hypertension, n     | 70 (40.0)           | 45 (35.2)              | 25 (53.2)            |
| Heart disease, n    | 20 (11.4)           | 14 (10.9)              | 6 (12.8)             |
| Cerebrovascular disease, n | 9 (5.1) | 5 (3.9) | 4 (8.5) |
| Hepatitis, n        | 20 (11.4)           | 15 (11.7)              | 5 (10.6)             |
| Obstructive jaundice, n | 78 (44.6) | 60 (46.9) | 18 (38.3) |
| Biliary drainage, n | 63 (36.0)           | 44 (34.4)              | 19 (40.4)            |
| **Laboratory values** |                     |                        |                      |
| WBC, /μL            | 5520 (2230–11020)   | 5165 (2230–11020)      | 5640 (3390–10430)    |
| Hemoglobin, g/dL    | 12.7 (7.2–16.5)     | 12.7 (7.2–16.3)        | 12.7 (8.8–16.5)      |
| Hematocrit, %       | 37.3 (22.8–46.1)    | 37.2 (22.8–46.1)       | 37.6 (25.3–45.9)     |
| Platelets, ×10⁹/μL  | 221 (64–539)        | 222 (64–513)           | 214 (118–539)        |
| CRP, mg/dL          | 0.15 (0.01–9.59)    | 0.17 (0.01–9.59)       | 0.12 (0.02–5.14)     |
| Albumin, g/dL       | 3.9 (2.0–5.7)       | 3.9 (2.0–5.7)          | 3.9 (2.7–4.7)        |
| Total protein, g/dL | 7.0 (4.9–8.9)       | 6.8 (4.9–8.9)          | 7.2 (5.9–8.0)        |
| Creatinine, mg/dL   | 0.67 (0.40–2.02)    | 0.64 (0.40–1.43)       | 0.72 (0.46–2.02)     |
| AST, U/L            | 28 (11–406)         | 29 (11–406)            | 26 (14–220)          |
| ALT, U/L            | 31 (9–627)          | 35 (9–627)             | 27 (10–175)          |
| GTP, U/L            | 51 (9–2579)         | 65 (9–1720)            | 38 (9–2579)          |
| Total bilirubin, mg/dL | 0.7 (0.2–32.7) | 0.8 (0.2–32.7) | 0.6 (0.2–4.6) |
| Amylase, U/L        | 74 (17–737)         | 74 (17–737)            | 75 (25–447)          |
| CA19-9, U/mL        | 87 (1–9675)         | 71 (1–9675)            | 152 (4–2114)         |
| CEA, ng/mL          | 2.7 (0.5–274)       | 2.7 (0.5–37.0)         | 3.2 (0.7–274)        |
| **Tumor factors**   |                     |                        |                      |
| Tumor size          |                     |                        |                      |
| TS1                 | 19 (10.9)           | 15 (11.7)              | 4 (8.5)              |
| TS2                 | 98 (56.0)           | 76 (59.4)              | 22 (46.8)            |
| TS3                 | 44 (14.1)           | 29 (22.7)              | 15 (31.9)            |
| TS4                 | 14 (8.0)            | 8 (6.3)                | 6 (12.8)             |
| **UICC 8th edition**|                     |                        |                      |
| T category, n       |                     |                        |                      |
| T1                  | 18 (10.3)           | 16 (12.5)              | 2 (4.3)              |
| T2                  | 85 (48.6)           | 79 (61.7)              | 6 (12.8)             |
| T3                  | 72 (41.1)           | 33 (25.8)              | 39 (83.0)            |
| T4                  | 0                   | 0                      | 0                    |
| N category, n       |                     |                        |                      |
| N0                  | 74 (42.3)           | 49 (38.3)              | 25 (53.2)            |
| N1                  | 64 (36.6)           | 49 (38.3)              | 15 (31.9)            |
| N2                  | 37 (21.1)           | 30 (23.4)              | 7 (14.9)             |
| M category, n       |                     |                        |                      |
| M0                  | 162 (92.6)          | 117 (91.4)             | 45 (95.7)            |

(Continued)
Binary logistic regression indicated that ALT and surgical procedure (DP) were significant predictors of massive IBL occurrence (Chi-Square = 48.977, df = 12, and p < 0.001). All twelve predictors explained 32.5% of the variability of massive IBL occurrence. The results of Hosmer and Lemeshow was p = 0.347. ALT and surgical procedure (DP) were significant at the 5% level (ALT Wald = 4.829, p = 0.028; DP Wald = 7.454, p = 0.006). The odds ratio for ALT was 1.007 (95% confidence interval (CI): 1.001–1.014) and for DP was 0.244 (95% CI: 0.089–0.672). The model correctly predicted 65.5% of cases without massive IBL and 75.0% of cases with massive IBL, giving an overall correct prediction rate of 70.3%.

### Decision tree analysis

Decision tree analysis was carried out on the training data set using 34 variables (Fig 2). The analysis automatically selected 14 predictive variables. The best predictor in the root node was the surgical procedure. Surgical procedure (including PD or not) was selected as the variable for the initial split. Among non-PD patients, the surgical procedure DP or TP was further identified as the variable of the second split. Among the patients with TP, creatinine was

### Table 1. Information of IBL

|                  | All cases (n = 175) | Training data (n = 128) | Testing data (n = 47) |
|------------------|---------------------|-------------------------|-----------------------|
| IBL, mL          | 750 (50–5600)       | 765 (90–3915)           | 650 (50–5600)         |
| IBL > 20% in CBV, n | 88 (50.3)           | 68 (53.1)               | 20 (42.6)             |
| IBL > 1000mL, n  | 60 (34.3)           | 46 (35.9)               | 14 (29.8)             |
| ABT, n           | 35 (20.0)           | 24 (18.8)               | 11 (23.4)             |

ABT, allogeneic red blood cell transfusion; CBV, circulating blood volume; IBL, intraoperative blood loss.

https://doi.org/10.1371/journal.pone.0259682.t002
Table 3. Comparison of the perioperative characteristics of massive IBL and non-massive IBL groups.

|                              | All cases (n = 175) | non-massive IBL (n = 87) | massive IBL (n = 88) | P value | Logistic regression |
|------------------------------|---------------------|--------------------------|----------------------|---------|---------------------|
|                              | Odds Ratio | 95% CI                 | P Value              | Odds Ratio | 95% CI                 | P Value |
| Gender, male, n              | 91 (52.0)  | 40 (46.0)              | 51 (58.0)            | 0.113    |                      |         |
| Age, year                    | 70 (43–87) | 71 (52–85)             | 69 (43–87)           | 0.018    | 0.957               | 0.910–1.006 | 0.083 |
| Body weight, kg              | 55.9 (34.0–85.0) | 55.9 (34.0–82.5)              | 55.9 (34.7–85.0)          | 0.512    |                      |         |
| Body mass index, kg/m²       | 22.0 (14.1–36.3) | 22.2 (17.1–33.3)              | 22.0 (14.1–36.3)          | 0.952    |                      |         |
| **Comorbidities**            |                      |                          |                      |         |                      |         |
| Diabetes mellitus, n         | 68 (38.9)  | 30 (34.5)              | 38 (43.2)            | 0.238    |                      |         |
| Cancer history, n            | 35 (20.0)  | 21 (24.1)              | 14 (15.9)            | 0.174    |                      |         |
| Hypertension, n              | 70 (40.0)  | 34 (39.1)              | 36 (40.9)            | 0.805    |                      |         |
| Heart disease, n             | 20 (11.4)  | 10 (11.5)              | 10 (11.4)            | 0.978    |                      |         |
| Cerebrovascular disease, n   | 9 (5.1)    | 3 (3.4)                | 6 (6.8)              | 0.254    |                      |         |
| Hepatitis, n                 | 20 (11.4)  | 9 (10.3)               | 11 (12.5)            | 0.654    |                      |         |
| Obstructive jaundice, n      | 78 (44.6)  | 26 (29.9)              | 52 (59.1)            | < 0.001  | 0.603               | 0.090–4.041 | 0.602 |
| Biliary drainage, n          | 63 (36.0)  | 21 (24.1)              | 42 (47.7)            | 0.001    | 1.267               | 0.229–7.009 | 0.786 |
| **Laboratory values**        |                      |                          |                      |         |                      |         |
| WBC, /µL                     | 5520 (2230–11020) | 5160 (2230–9980)              | 5335 (2410–11020)          | 0.227    |                      |         |
| Hemoglobin, g/dL             | 12.7 (7.2–16.5) | 12.7 (7.2–15.9)              | 12.7 (8.8–16.5)           | 0.829    |                      |         |
| Hematocrit, %                | 37.3 (22.8–46.1) | 37.2 (22.8–46.1)              | 37.2 (26.7–45.8)           | 0.793    |                      |         |
| Platelets, x10³/µL           | 221 (64–539) | 214 (96–539)              | 223 (64–513)            | 0.430    |                      |         |
| CRP, mg/dL                   | 0.15 (0.01–9.59) | 0.11 (0.02–9.59)              | 0.23 (0.01–6.50)           | 0.057    |                      |         |
| Albumin, g/dL                | 3.9 (2.0–5.7) | 4.0 (2.5–5.7)              | 3.9 (2.0–4.9)            | 0.005    | 0.457               | 0.198–1.054 | 0.066 |
| Total protein, g/dL          | 7.0 (4.9–8.9) | 7.1 (5.4–8.9)              | 6.9 (4.9–8.1)            | 0.324    |                      |         |
| Creatinine, mg/dL            | 0.67 (0.40–2.02) | 0.67 (0.43–2.02)              | 0.67 (0.40–1.69)           | 0.970    |                      |         |
| AST, U/L                     | 28 (11–406) | 24 (14–287)              | 34 (11–406)            | 0.001    | 1                      |         |
| ALT, U/L                     | 31 (9–627)  | 23 (9–361)              | 45 (9–627)            | < 0.001  | 1.007               | 1.001–1.014 | 0.028 |
| GTP, U/L                     | 51 (9–2579) | 30 (9–1422)              | 113 (11–2579)           | < 0.001  | 0.999               | 0.998–1.001 | 0.219 |
| Total bilirubin, mg/dL       | 0.7 (0.2–32.7) | 0.6 (0.2–32.7)              | 0.9 (0.3–24.1)           | 0.015    | 0.971               | 0.869–1.085 | 0.971 |
| Amylase, U/L                 | 74 (17–737) | 71 (17–446)              | 81 (25–737)            | 0.197    |                      |         |
| CA19-9, U/mL                 | 87 (1–9675) | 62 (1–3199)              | 113 (1–9675)           | 0.248    |                      |         |
| CEA, ng/mL                   | 2.7 (0.5–274) | 2.7 (0.6–274)              | 3.0 (0.5–23.9)           | 0.272    |                      |         |
| **Tumor factors**            |                      |                          |                      |         |                      |         |
| Tumor size                   |                      |                          | 0.799                |         |                      |         |
| TS1                          | 19 (10.9)  | 11 (12.6)              | 8 (9.1)               |         |                      |         |
| TS2                          | 98 (56.0)  | 47 (54.0)              | 51 (58.0)             |         |                      |         |
| TS3                          | 44 (14.1)  | 23 (26.4)              | 21 (23.9)             |         |                      |         |
| TS4                          | 14 (8.0)   | 6 (6.9)                | 8 (9.1)               |         |                      |         |
| UICC 8th edition             |                      |                          | 0.602                |         |                      |         |
| T category, n                |                      |                          | 0.060                |         |                      |         |
| T1                           | 18 (10.3)  | 10 (11.5)              | 8 (9.1)               |         |                      |         |
| T2                           | 85 (48.6)  | 39 (44.8)              | 46 (52.3)             |         |                      |         |
| T3                           | 72 (41.1)  | 38 (43.7)              | 34 (38.6)             |         |                      |         |
| T4                           | 0          | 0                     | 0                    |         |                      |         |
| N category, n                |                      |                          | 0.046                |         |                      |         |
| N0                           | 74 (42.3)  | 44 (50.6)              | 30 (34.1)             |         |                      |         |
| N1                           | 64 (36.6)  | 30 (34.5)              | 34 (38.6)             | 1.065    | 0.467–2.426         | 0.881 |
| N2                           | 37 (21.1)  | 13 (14.9)              | 24 (27.3)             | 1.508    | 0.570–3.986         | 0.408 |
| M category, n                |                      |                          | 0.399                |         |                      |         |

(Continued)
identified as the variable of the third split, with an optimal cut-off value of \( \leq 0.705 \) mg/dL. In this node, all patients under 0.705 mg/dL experienced massive IBL.

The outcome of patients with DP was split by GTP levels, with an optimal cut-off value of \( \leq 98.952 \) U/L. In this node, all patients over 98.952 U/L experienced massive IBL. The outcome of other patients with DP was determined by an additional predictor such as creatinine, carbohydrate antigen 19–9 (CA19-9), total bilirubin, ALT or hematocrit.

Among the patients who underwent PD, diabetes mellitus (DM) was selected as the variable of the second split. Of the 21 patients with DM, the rate of massive IBL occurrence was 85.7%. The outcome for non-DM patients undergoing PD was determined by an additional predictor such as ALT, total protein, carcinoembryonic antigen (CEA), or age.

With all the variables in the model, the decision tree achieved an accuracy of 80.5% (sensitivity of 98.5% and specificity of 60.0%) for the training data set. In the testing data set, the decision tree achieved an accuracy of 80.9%, sensitivity of 100.0%, and specificity of 66.7%.

### Table 3. (Continued)

| UICC Stage, n | All cases (n = 175) | non-massive IBL (n = 87) | massive IBL (n = 88) | P value |
|---------------|---------------------|--------------------------|----------------------|---------|
| M0            | 162 (92.6)          | 82 (94.3)                | 80 (90.9)            |         |
| M1\(^i\)      | 13 (6.9)            | 5 (5.7)                  | 8 (9.1)              | 0.212   |
| Operative factors |                     |                          |                      |         |
| Surgical procedure, n | 106 (60.6)         | 37 (42.5)                | 69 (78.4)            | < 0.001 |
| Pancreatecoduodenumectomy | 106 (60.6)         | 37 (42.5)                | 69 (78.4)            |         |
| Distal pancreatectomy | 59 (33.7)          | 47 (54.0)                | 12 (13.6)            | 0.244   |
| Total pancreatectomy | 10 (5.7)           | 3 (3.4)                  | 7 (8.0)              | 1.991   |
| Portal vein resection, n | 28 (16.0)          | 6 (6.9)                  | 22 (25.0)            | 0.001   |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA19-9, carbohydrate antigen 19–9; CEA, carcinoembryonic antigen; CI, confidence interval; CRP, C-reactive protein; GTP, glutamyl transpeptidase; IBL, intraoperative blood loss; TS, tumor size; UICC, Union for International Cancer Control; WBC, white blood cell; \(^i\): All of the patients were diagnosed with M1 due to positive lymph nodes other than the regional lymph nodes. \(^i\): Excluded due to multicollinearity with ALT.

### Table 4. Comparison of the operative outcomes of the massive IBL and non-massive IBL groups.

| ABT, n | All cases (n = 175) | non-massive IBL (n = 87) | massive IBL (n = 88) | P value |
|--------|---------------------|--------------------------|----------------------|---------|
| ABT, allogeneic red blood cell transfusion; IBL, intraoperative blood loss; ISGPF, the International Study Group of Pancreatic Fistula; ISGPS, the International Study Group of Pancreatic Surgery. | | | | |

https://doi.org/10.1371/journal.pone.0259682.t003

https://doi.org/10.1371/journal.pone.0259682.t004
Discussion

We defined the variables that could identify individuals at a risk for massive IBL in surgery for patients with resectable PDAC. Furthermore, we developed a decision tree to predict massive IBL.

The negative impact of IBL on outcomes after pancreatic surgery has long been suspected [29–34]; however, there have been few reports demonstrating risk factors for IBL [32, 33].
Rystedt et al. retrospectively analyzed 1864 patients who had undergone a PD in the Swedish National Pancreatic and Periampullary Cancer Registry. The national study on resectable periampullary tumors shows that the preoperative independent risk factors associated with major IBL (≥1000 mL) were male sex, body mass index ≥25 kg/m², preoperative biliary drainage, C-reactive protein ≥12 mg/L, and neo-adjuvant chemotherapy treatment [32]. Seykora et al. conducted a multi-institutional retrospective study and precisely evaluated 5323 PD patients who had been treated for either benign or malignant disease by 62 surgeons from 17 institutions [33]. They demonstrated that factors significantly associated with increased IBL (>1300 mL) were trans-anastomotic stent placement, neoadjuvant chemotherapy, pancreaticogastrostomy reconstruction, multiorgan or vascular resection, and elevated operative time (>435 min). Furthermore, they showed that female sex, small duct (≤2 mm), soft gland, minimally invasive approach, pylorus preservation, biological sealant use, and institutional volume (≥67/year) were associated with decreased IBL (<300 mL). Those large cohort studies, which provided novel and significant insight to us, were analyzed using multivariable logistic regression modeling to identify the independent risk factors for massive IBL. This method has been traditionally performed in clinical studies, but there have been certain limitations, such as selecting the variables, confounding factors, and multicollinearity, as shown in this study. To resolve these problems, we attempted to make a prediction model using a decision tree analysis. This study is the first report describing a decision tree used to predict massive IBL in pancreatic surgery for resectable PDAC. The innovative value of this study is less about the excellent accuracy of the decision tree model, but more about demonstrating the potential of a novel approach for this type of prediction.

The decision tree is a machine-learning model. It comprises decision rules based on optimal feature cutoff values that recursively split independent variables into different groups and predict an outcome hierarchically [35]. The advantages of decision tree algorithms are that they are logic-based, easily interpretable, and straightforward [36]. Moreover, this machine learning method can handle both continuous and categorical variables, which suit a clinical study that includes mixed variables.

In establishing this decision tree model, surgical procedure was the first node in predicting massive IBL. Then, factors related to liver function tests, such as GTP and ALT, were usually identified as the split variable. Tumor markers, such as CA19-9 and CEA, were also identified as the split variable. These would be easily acceptable to surgeons based on their long experience.

Our model identified that hepatobiliary enzymes were risk factors for massive IBL. One of the possible explanations is that the elevation of hepatobiliary enzymes is caused by cholangitis due to bile duct obstruction. Generally, inflammation can induce neovascularization during the healing process. In the animal cholangitis model, microvessels were richly developed around the dilated bile duct [37]. It was speculated that vascular endothelial growth factor (VEGF) plays a central role in this neovascularization. Ren et al. demonstrated that overexpression of VEGF was more prominent not only in the surrounding microvessels but also in bile duct epithelium with inflammation [37]. Unfortunately, before surgery, predicting the degree of VEGF and neovascularization around the bile duct is extremely hard. Thus, it is better for us to consider patients with elevated hepatobiliary enzyme, even after biliary drainage, as at risk for massive IBL.

In this study, 88 of the 175 patients (50.3%) were included in the massive IBL group. The factors which may have led to a relatively high proportion of massive IBL are as follows. First, we defined massive IBL as more than 20% of the estimated circulating blood volume, based on the model of Lundsgaard-Hansen [27]. This definition of massive IBL is stricter than that of previous studies [32, 33]. If we define massive IBL as bleeding of over 1000 ml, 60 patients
(34.3%) would be included in the massive IBL group. Second, at our institution, any fluid loss from the abdominal cavity including ascites, bile, and lymphatics is considered to be intraoperative bleeding. Thus, only 20% of the patients required intraoperative allogeneic RBC transfusion, which is a similar rate to that of previous reports. Third, this study included only a small number of minimally invasive surgery cases. Finally, at our institution, approximately 20 different surgeons operated during the study period. Previous studies reported that surgeon volume was an important determinant of IBL [38, 39]. In short, surgeons with more experience are more likely to reduce IBL compared with their less-experienced peers. Ideally, all surgery should be performed by the most experienced surgeons. However, it is sometimes difficult to achieve this in real clinical situations. We believe that our study should be useful, especially to less-experienced surgeons and their patients.

The present study, using a decision tree, has several limitations. First, this is a retrospective single-institution cohort study. In addition, the patient population was small. If we had access to additional training data, we could achieve even higher prediction accuracy. Furthermore, we could use other machine learning methods such as some sort of neural network. Actually, we attempted the use of a neural network and achieved an accuracy of 95.3% for the same training data set. However, the accuracy of the testing data set dropped to 54.1%. In contrast to the neural network, a decision tree visualizes a flowchart that allows appropriate treatment options for each patient depending on modifiable conditions based on that patient. Another important limitation is that the accuracy of the established model is not high enough. Thus, it would be more beneficial to focus the tree on partial data, not the entirety, and interpret them locally. To establish clinical applications, sufficient training and testing data sets are fundamental requirements for decision trees as well as neural networks. A new approach using machine learning methods that could take advantage of huge database such as national or regional data sets would be attractive for both clinicians treating PDAC and their patients.

Conclusions

The present study, using a decision tree, has provided a new potential approach to predict massive IBL in surgery for resectable PDAC patients. To establish a more accurate prediction model for clinical application, conducting a study using a huge data set is a hope for the future.

Supporting information

S1 File. Our study’s minimal data set.
(TXT)

S2 File. Source code.
(PY)

S3 File.
(DOCX)

Acknowledgments

We sincerely thank Shari Joy Berman for professionally editing the English draft of this manuscript.

Author Contributions

Conceptualization: Taiichi Wakiya.
**Data curation:** Taiichi Wakiya, Keinosuke Ishido, Norihisa Kimura, Hayato Nagase, Shunsuke Kubota, Hiroaki Fujita, Yusuke Hagiwara, Taishu Kanda.

**Formal analysis:** Taiichi Wakiya, Yoshihiro Sasaki.

**Methodology:** Taiichi Wakiya, Yoshihiro Sasaki.

**Writing – original draft:** Taiichi Wakiya.

**Writing – review & editing:** Masashi Matsuzaka, Yoshihiro Sasaki, Kenichi Hakamada.

**References**

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68(6):394–424. Epub 2018/09/13. https://doi.org/10.3322/caac.21492 PMID: 30207593.

2. Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016; 2:16022. Epub 2016/05/10. https://doi.org/10.1038/nrdp.2016.22 PMID: 27158978.

3. Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today. 2008; 38(11):1021–8. Epub 2008/10/30. https://doi.org/10.1007/s00595-007-3745-8 PMID: 18958561.

4. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007; 246(2):173–80. Epub 2007/08/02. https://doi.org/10.1097/SLA.0b013e3180691579 PMID: 17667493.

5. Ahola R, Sand J, Laukkarien J. Pancreatic resections are not only safest but also most cost-effective when performed in a high-volume centre: A Finnish register study. Panreatology. 2019; 19(5):769–74. Epub 2019/06/27. https://doi.org/10.1016/j.pan.2019.06.007 PMID: 31239104.

6. Amini N, Spolverato G, Gupta R, Margonis GA, Kim Y, Wagner D, et al. Impact Total Psoas Volume on Short- and Long-Term Outcomes in Patients Undergoing Curative Resection for Pancreatic Adenocarcinoma: a New Tool to Assess Sarcopenia. J Gastrointest Surg. 2015; 19(9):1593–602. https://doi.org/10.1007/s11605-015-2835-y PMID: 25925237.

7. de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, et al. Impact of nationwide centralization of pancreatectoduodenectomy on hospital mortality. Br J Surg. 2012; 99(3):404–10. Epub 2012/01/13. https://doi.org/10.1002/bjs.8664 PMID: 22237731.

8. Gooiker GA, Lemmens VE, Besselink MG, Busch OR, Bonsing BA, Molenaar IQ, et al. Impact of centralization of pancreatic cancer surgery on resection rates and survival. Br J Surg. 2014; 101(8):1000–5. Epub 2014/05/23. https://doi.org/10.1002/bjs.9468 PMID: 24845490.

9. Onete VG, Besselink MG, Salsbach CM, Van Eijck CH, Busch OR, Gouma DJ, et al. Impact of centralization of pancreatectoduodenectomy on reported radical resections rates in a nationwide pathology database. HPB (Oxford). 2015; 17(8):736–42. Epub 2015/06/04. https://doi.org/10.1111/hpb.12425 PMID: 26037776.

10. Hachey K, Morgan R, Rosen A, Rao SR, McNenery D, Tseng J, et al. Quality Comes with the (Anatomic) Territory: Evaluating the Impact of Surgeon Operative Mix on Patient Outcomes After Pancreatectoduodenectomy. Ann Surg Oncol. 2018; 25(13):3795–803. Epub 2018/09/07. https://doi.org/10.1245/s10434-018-6732-y PMID: 30187279.

11. Snyder RA, Prakash LR, Nogueras-Gonzalez GM, Kim MP, Aloia TA, Vauthey JN, et al. Perioperative blood transfusions for vein resection during pancreatectoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. HPB (Oxford). 2019; 21(7):841–8. Epub 2018/12/07. https://doi.org/10.1016/j.hpb.2018.02.018 PMID: 30501986.

12. Ecker BL, Simmons KD, Zeheer S, Poe SL, Bartlett EK, Drebil JA, et al. Blood Transfusion in Major Abdominal Surgery for Malignant Tumors: A Trend Analysis Using the National Surgical Quality Improvement Program. JAMA surgery. 2016; 151(8):518–25. Epub 2016/01/15. https://doi.org/10.1001/jamasurg.2015.5094 PMID: 26763765.

13. Kneuertz PJ, Patel SH, Chu CK, Malinell SK, Sarmiento JM, Delman KA, et al. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreatectoduodenectomy for ductal adenocarcinoma. Ann Surg Oncol. 2011; 18(5):1327–34. Epub 2011/03/04. https://doi.org/10.1245/s10434-010-1476-3 PMID: 21369744.

14. Opelz G, Sengar DP, Mickey MR, Terasaka PI. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc. 1973; 5(1):253–9. Epub 1973/03/01. PMID: 4572096.
15. Opelz G, Terasaki PI. Improvement of kidney-graft survival with increased numbers of blood transfusions. N Engl J Med. 1978; 299(15):799–803. Epub 1978/10/12. https://doi.org/10.1056/NEJM19781022991503 PMID: 357971.

16. Remy KE, Hall MW, Chollete J, Juffermans NP, Nicol K, Doctor A, et al. Mechanisms of red blood cell transfusion-related immunomodulation. Transfusion. 2018; 58(3):804–15. Epub 2018/02/01. https://doi.org/10.1111/trf.14488 PMID: 29383722.

17. Nakashiki K, Kanda M, Kodera Y. Long-lasting discussion: Adverse effects of intraoperative blood loss and allogeneic transfusion on prognosis of patients with gastric cancer. World J Gastroenterol. 2019; 25(22):2743–51. Epub 2019/06/27. https://doi.org/10.3748/wjg.v25.i22.2743 PMID: 31235997.

18. Peng P, Hyder O, Firoozmand A, Kneuertz P, Schulick RD, Huang D, et al. Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012; 16(8):1478–86. https://doi.org/10.1007/s11605-012-1923-5 PMID: 22692586.

19. Lee B, Han HS, Yoon YS, Cho JY, Lee JS. Impact of Preoperative Malnutrition, based on Albumin Level and Body Mass Index, on Operative Outcomes in Patients with Pancreatic Head Cancer. J Hepatobiliary Pancreat Sci. 2020. Epub 2020/11/01. https://doi.org/10.1002/jhbp.858 PMID: 33128839.

20. Mavros MN, Xu L, Maqsood H, Gani F, Ejaz A, Spolverato G, et al. Perioperative Blood Transfusion and the Prognosis of Pancreatic Cancer Surgery: Systematic Review and Meta-analysis. Ann Surg Oncol. 2015; 22(13):4382–91. Epub 2015/08/22. https://doi.org/10.1245/s10434-015-4823-6 PMID: 26293837.

21. Sutton JM, Kooby DA, Wilson GC, Squires MH 3rd, Hanseman DJ, Mathe1 SK, et al. Perioperative blood transfusion is associated with decreased survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma: a multi-institutional study. J Gastrointest Surg. 2014; 18(9):1575–87. Epub 2014/06/20. https://doi.org/10.1007/s11605-014-2567-4 PMID: 24944151.

22. Abe T, Amano H, Hanada K, Minami T, Yonehara S, Hattori M, et al. Perioperative Red Blood Cell Transfusion Is Associated with Poor Long-term Survival in Pancreatic Adenocarcinoma. Anticancer Res. 2017; 37(10):5863–70. Epub 2017/10/07. https://doi.org/10.21873/anticanres.12031 PMID: 28982913.

23. Kim SY, Choi M, Hwang HK, Rho SY, Lee WJ, Kang CM. Intraoperative Transfusion is Independently Associated with a Worse Prognosis in Resected Pancreatic Cancer—a Retrospective Cohort Analysis. Journal of clinical medicine. 2020; 9(3). Epub 2020/03/08. https://doi.org/10.3390/jcm9030689 PMID: 32143434.

24. Hwang HK, Jung MJ, Lee SH, Kang CM, Lee WJ. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy. J Hepatobiliary Pancreat Sci. 2016; 23(8):497–507. Epub 2016/06/15. https://doi.org/10.1002/jhbp.368 PMID: 27295957.

25. Kanda T, Wakiya T, Ishido K, Kimura N, Nagase H, Kubota I, et al. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching Analysis. Pancreas. 2021. in press.

26. Pedregosa F. Scikit-learn: Machine learning in python. J Machine Learn Res. 2011; 12:2825–30.

27. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G. STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery. Int J Surg. 2019; 72:156–65. Epub 2019/11/11. https://doi.org/10.1016/j.ijsu.2019.11.002 PMID: 31704426.

28. Lundsgaard-Hansen P. Component therapy of surgical hemorrhage: red cell concentrates, colloids and crystalloids. Bibliotheca haematologica. 1980;(46):147–69. Epub 1980/01/01. https://doi.org/10.1159/00043055 PMID: 7378036.

29. Braga M, Capretti G, Pecorelli N, Balzano G, Doglioni C, Ariotti R, et al. A prognostic score to predict major complications after pancreatectoduodenectomy. Ann Surg. 2011; 254(5):702–7; discussion 7–8. https://doi.org/10.1097/SLA.0b013e3182590c2b PMID: 22042466.

30. Callery MP, Pratt WB, Kent TS, Chaikof EL, Vollmer CM. A prospectively validated clinical risk score accurately predicts pancreatic fistula after pancreatectoduodenectomy. J Am Coll Surg. 2013; 216(1):1–14. https://doi.org/10.1016/j.jamcollsurg.2012.09.002 PMID: 23122555.

31. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber HA. Improved Survival Following Pancreatectoduodenectomy to Treat Adenocarcinoma of the Pancreas: The Influence of Operative Blood Loss. Archives of Surgery. 2008; 143(12):1166–71. https://doi.org/10.1001/archsurg.143.12.1166 PMID: 19075167.

32. Rystedt J, Tingstedt B, Ansorge C, Nilsson J, Andersson B. Major intraoperative bleeding during pancreatectoduodenectomy—preoperative biliary drainage is the only modifiable risk factor. HPB (Oxford). 2019; 21(3):268–74. Epub 2018/09/02. https://doi.org/10.1016/j.hpb.2018.07.024 PMID: 30170979.
33. Seykora TF, Ecker BL, McMillan MT, Maggino L, Beane JD, Fong ZV, et al. The Beneficial Effects of Minimizing Blood Loss in Pancreatoduodenectomy. Ann Surg. 2019; 270(1):147–57. Epub 2018/03/01. https://doi.org/10.1097/SLA.0000000000002714 PMID: 29489483.

34. Trudeau MT, Casciani F, Maggino L, Seykora TF, Asbun HJ, Ball CG, et al. The Influence of Intraoperative Blood Loss on Fistula Development Following Pancreatoduodenectomy. Annals of Surgery. 9000; Publish Ahead of Print. https://doi.org/10.1097/sla.0000000000004549 00000658-90000000-94033. PMID: 33201132

35. Wu X, Kumar V, Ross Quinlan J, Ghosh J, Yang Q, Motoda H, et al. Top 10 algorithms in data mining. Knowledge and Information Systems. 2008; 14(1):1–37. https://doi.org/10.1007/s10115-007-0114-2

36. Lakshmi BN, Indumathi TS, Ravi N. A Study on C.5 Decision Tree Classification Algorithm for Risk Predictions During Pregnancy. Procedia Technology. 2016; 24:1542–9. https://doi.org/10.1016/j.protcy.2016.05.128

37. Ren XS, Sato Y, Harada K, Sasaki M, Yoneda N, Lin ZH, et al. Biliary infection may exacerbate biliary cystogenesis through the induction of VEGF in cholangiocytes of the polycystic kidney (PCK) rat. Am J Pathol. 2011; 179(6):2845–54. Epub 2011/10/22. https://doi.org/10.1016/j.ajpath.2011.08.028 PMID: 22015458.

38. Casciani F, Trudeau MT, Asbun HJ, Ball CG, Bassi C, Behrman SW, et al. Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. Surgery. 2021; 169(4):708–20. Epub 2021/01/03. https://doi.org/10.1016/j.surg.2020.11.022 PMID: 33386129.

39. Schmidt CM, Turrini O, Parikh P, House MG, Zyromski NJ, Nakeeb A, et al. Effect of Hospital Volume, Surgeon Experience, and Surgeon Volume on Patient Outcomes After Pancreatodudodenectomy: A Single-Institution Experience. Archives of Surgery. 2010; 145(7):634–40. https://doi.org/10.1001/archsurg.2010.118 PMID: 20644125